

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/029,206        |
| Filing Date            | December 21, 2001 |
| First Named Inventor   | Khan et al.       |
| Group Art Unit         | 1651              |
| Examiner Name          | To be assigned    |
| Attorney Docket Number | 2183-5222US       |

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/029,206        |
| Filing Date            | December 21, 2001 |
| First Named Inventor   | Khan et al.       |
| Group Art Unit         | 1651              |
| Examiner Name          | To be assigned    |
| Attorney Docket Number | 2183-5222US       |

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item<br>(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),<br>publisher, city and/or country where published. | T <sup>2</sup> |
|------------------------|--------------------------|---|----------------|
| [Signature]            |                          | PCT International Search Report, PCT/NL01/00259, dated December 18, 2001, 3 pages.  |                |
|                        |                          | PCT International Preliminary Examination Report, PCT/NL99/00313, dated July 21, 2000, 6 pages.   |                |
|                        |                          | PCT International Search Report, PCT/EP99/00313, dated November 29, 1999, 3 pages.  |                |
|                        |                          | Lang et al., "Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin", <u>AIDS</u> 1997, Vol. 11, No. 11, pp.1333-1340.   |                |
|                        |                          | Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease", <u>Nature Medicine</u> , April 1998, Vol. 4, No. 4, pp. 428-434.   |                |
|                        |                          |   |                |
|                        |                          |   |                |
|                        |                          |   |                |
|                        |                          |   |                |
|                        |                          |   |                |
|                        |                          |   |                |
|                        |                          |   |                |
|                        |                          |   |                |

Examiner  
Signature

[Signature]


Date  
Considered

12/13/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number

10/029,206

Filing Date

December 21, 2001

First Named Inventor

Khan et al.

Group Art Unit

1651

Examiner Name

To be assigned

Attorney Docket Number

2183-5222US

**U.S. PATENT DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|------------------------|--------------------------|--|--------------------------------|--|---|
|                        |                          | Number - Kind Code <sup>2</sup> (if known) |                                |  |   |
|                        |                          | #US-5,380,668                              | 01-10-1995                     | Herron   |   |
|                        |                          | #US- 2003/0186244 A1                       | 10-02-2003                     | Margus et al.                                      |   |
|                        |                          | #US- 2003/0113733 A1                       | 06-19-2003                     | Khan et al.  |   |
|                        |                          | #US- 2003/0119720 A1                       | 06-26-2003                     | Khan et al.  |   |
|                        |                          | #US- 2002/0064501 A1                       | 05-30-2002                     | Khan et al.  |   |
|                        |                          | #US- 2003/0166556 A1                       | 09-04-2003                     | Khan et al.  |   |
|                        |                          | #US- 2003/0215434 A1                       | 11-20-2003                     | Khan et al.  |   |
|                        |                          | #US- 2003/0219425 A1                       | 11-27-2003                     | Khan et al.  |   |
|                        |                          | #US- 2003/0220257 A1                       | 11-27-2003                     | Benner et al.                                      |   |
|                        |                          | #US- 2003/0220258 A1                       | 11-27-2003                     | Benner et al.                                      |   |
|                        |                          | #US- 2003/0220259 A1                       | 11-27-2003                     | Benner et al.                                      |   |
|                        |                          | #US- 2003/0220260 A1                       | 11-27-2003                     | Khan et al.  |   |
|                        |                          | #US- 2003/0220261 A1                       | 11-27-2003                     | Khan et al.  |   |
|                        |                          | #US- 2003/0224995 A1                       | 12-04-2003                     | Khan et al.  |   |
|                        |                          | #US- 2004/0013661 A1                       | 01-22-2004                     | Wensvoort et al.                                   |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |

**FOREIGN PATENT DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant Passages or<br>Relevant Figures Appear | T <sup>6</sup> |
|------------------------|--------------------------|---|--------------------------------|---|---|----------------|
|                        |                          | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) |                                |   |   |                |
|                        |                          | #WO 03/029292 A2  | 04-10-2003                     | Erasmus Universiteit<br>Rotterdam                     |   |                |
|                        |                          |   |                                |   |   |                |
|                        |                          |   |                                |   |   |                |
|                        |                          |   |                                |   |   |                |

Examiner  
SignatureDate  
Considered

12/13/04

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the

Office in the following prior application:

Serial No.: 09/821,380


Filed: March 29, 2001

For: IMMUNOREGULATOR, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



+

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

4

### Complete if Known

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/029,206        |
| Filing Date            | December 21, 2001 |
| First Named Inventor   | Khan et. al.      |
| Group Art Unit         | 1651              |
| Examiner Name          | To be assigned    |
| Attorney Docket Number | 2183-5222US       |

### U.S. PATENT DOCUMENTS

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|------------------------|--------------------------|--|--------------------------------|--|---|
|                        |                          | Number - Kind Code <sup>2</sup> (if known) |                                |  |   |
|                        |                          | #US- 4,977,244                             | 12-11-1990                     | Muchmore et al.                                    |   |
|                        |                          | #US- 5,677,275                             | 10-14-1997                     | Lunardi-Iskandar et al.                            |   |
|                        |                          | #US- 5,877,148                             | 03-02-1999                     | Lunardi-Iskandar et al.                            |   |
|                        |                          | #US- 5,958,413                             | 09-28-1999                     | Anagnostopoulos et al.                             |   |
|                        |                          | #US- 5,968,513                             | 10-19-1999                     | Gallo et al.                                       |   |
|                        |                          | #US- 5,997,871                             | 12-07-1999                     | Gallo et al.                                       |   |
|                        |                          | #US- 2003/0049273 A1                       | 03-13-2003                     | Gallo et al.                                       |   |
|                        |                          | #US- 6,583,109 B1                          | 06-24-2003                     | Gallo et al.                                       |   |
|                        |                          | #US- 6,596,688 B1                          | 07-22-2003                     | Gallo et al.                                       |   |
|                        |                          | #US- 6,620,416 B1                          | 09-16-2003                     | Gallo et al.                                       |   |
|                        |                          | #US- 2002/0064501                          | 05-30-2002                     | Khan et al.  |   |
|                        |                          | #US- 2002/0041871                          | 04-11-2002                     | Brudnak  |   |
|                        |                          | #US- 5,851,997                             | 12-22-1998                     | Harris   |   |
|                        |                          | #US- 6,489,296                             | 12-03-2002                     | Grinnell et al.                                    |   |
|                        |                          | US- 5,854,004                              | 12-1998                        | Czernilofsky et al.                                |   |
|                        |                          | US- 6,361,992 B1                           | 03-2002                        | Szkudlinski et al.                                 |   |
|                        |                          | US-  |                                |  |   |

### FOREIGN PATENT DOCUMENTS

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant Passages or<br>Relevant Figures Appear | T <sup>6</sup> |
|------------------------|--------------------------|---|--------------------------------|---|---|----------------|
|                        |                          | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) |                                |   |   |                |
|                        |                          | #WO 01/10907 A2   | 02-15-2001                     | University of Maryland                                |   |                |
|                        |                          | #WO 01/11048 A2   | 02-15-2001                     | University of Maryland                                |   |                |
|                        |                          | #WO 01/72831  | 10-04-2001                     | Erasmus Universiteit                                  |   |                |
|                        |                          | #2 706 772  | 12-30-1994                     | Vacsyn  |   |                |
|                        |                          | #EP 1 138 692 A1  | 10/04/2001                     | Erasmus Universiteit<br>Rotterdam                     |   |                |

Examiner  
Signature

Date  
Considered

12/23/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

+



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/029,206        |
| Filing Date            | December 21, 2001 |
| First Named Inventor   | Khan et. al.      |
| Group Art Unit         | 1651              |
| Examiner Name          | To be assigned    |
| Attorney Docket Number | 2183-5222US       |

Sheet 2 of 4

**U.S. PATENT DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Document Number                            | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of<br>Cited Document | Pages, Columns, Lines, Where Relevant<br>Passages or Relevant<br>Figures Appear |
|------------------------|--------------------------|--|--------------------------------|--|---|
|                        |                          | Number - Kind Code <sup>2</sup> (if known) |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |
|                        |                          | US-  |                                |  |   |

**FOREIGN PATENT DOCUMENTS**


| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited<br>Document | Pages, Columns, Lines,<br>Where Relevant Passages or<br>Relevant Figures Appear | T <sup>6</sup> |
|------------------------|--------------------------|---|--------------------------------|---|---|----------------|
|                        |                          | Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known) |                                |   |   |                |
|                        |                          | #EP 1 300 418   | 04-09-2003                     | Erasmus Universiteit<br>Rotterdam                     |   |                |
|                        |                          | #WO 98/35691  | 08-20-1998                     | Proscript, Inc.                                       |   |                |
|                        |                          | #WO 02/085117   | 10-31-2002                     | Eisai Co., Ltd.                                       |   |                |
|                        |                          | #DE 3715662   | 11-19-1987                     | The Wellcome<br>Foundation Ltd.                       |   |                |
|                        |                          | #DE 19953339  | 05-17-2001                     | Goldham Pharma<br>GmbH                                |   |                |
|                        |                          | #96/04008   | 02-15-1996                     | Government of the<br>United States                    |   |                |
|                        |                          | #97/49373   | 12-31-1997                     | University of Maryland<br>Biotechnology Institute     |   |                |
|                        |                          | #97/49418   | 12-31-1997                     | University of Maryland<br>Biotechnology Institute     |   |                |
|                        |                          | #97/49432   | 12-31-1997                     | University of Maryland<br>Biotechnology Institute     |   |                |

|                       |  |                    |          |
|-----------------------|--|--------------------|----------|
| Examiner<br>Signature |  | Date<br>Considered | 12/13/04 |
|-----------------------|--|--------------------|----------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

4

**Complete if Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/029,206        |
| Filing Date            | December 21, 2001 |
| First Named Inventor   | Khan et. al.      |
| Group Art Unit         | 1651              |
| Examiner Name          | To be assigned    |
| Attorney Docket Number | 2183-5222US       |

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**


| Examiner<br>Initials * | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|------------------------|--------------------------|---|----------------|
|                        |                          | #International Search Report, International Application No. PCT/NL02/00639, mailed August 4, 2003 (8 pages).  |                |
|                        |                          | #CHRISTMAN et al., Nuclear factor kappaB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy, Intens Care Med, 1998, pp. 1131-38, Vol. 24.  |                |
|                        |                          | #JYONOUCHI et al., Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression, J Neuroim., 2001, pp. 170-79, Vol. 120.                     |                |
|                        |                          | #KANUNGO et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, Vol. 20.  |                |
|                        |                          | #ROHRIG et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblatt Bakt, 1999, pp. 89-99, Vol. 289.   |                |
|                        |                          | #TAK et al., NF-kappaB: a key role in inflammatory diseases, J Clin Invest., 2001, pp. 7-11, Vol. 107.  |                |
|                        |                          | #TAN et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, Vol. 55.   |                |
|                        |                          | #TOVEY et al., Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-21, Vol. 19.   |                |

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

4

**Complete if Known**

|                        |                   |
|------------------------|-------------------|
| Application Number     | 10/029,206        |
| Filing Date            | December 21, 2001 |
| First Named Inventor   | Khan et. al.      |
| Group Art Unit         | 1651              |
| Examiner Name          | To be assigned    |
| Attorney Docket Number | 2183-5222US       |

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials * | Cite<br>No.† | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item<br>(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher,<br>city and/or country where published. | T <sup>2</sup> |
|------------------------|--------------|---|----------------|
|                        |              | #ALBINI, A., et al., "Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG and somatostatin,"<br>17 CLINICAL & EXPERIMENTAL METASTASIS 739 (1999).   |                |
|                        |              | #BLACKWELL, Timothy S., et al., "The Role of Nuclear Factor-kB in Cytokine Gene Regulation," 17 AM. J. RESPIR. CELL<br>MOL. BIOL. 3-9 (1997).   |                |
|                        |              | #KELLER, S., et al., "Human Chorionic Gonadotropin (hCG) Is a Potent Angiogenic Factor for Uterine Endothelial Cells <i>in<br/>Vitro</i> ," 20(5-6) PLACENTA, page A37 (July 1999).   |                |
|                        |              | #KHAN, Nisar A., et al., "Inhibition of Diabetes in NOD Mice by Human Pregnancy Factor," 62(12) HUMAN<br>IMMUNOLOGY 1315-1323 (December 2001).  |                |
|                        |              | #KHAN, Nisar A., et al., "Inhibition of Septic Shock in Mice by an Oligopeptide From the $\beta$ -Chain of Human Chorionic<br>Gonadotrophin Hormone," 63(1) HUMAN IMMUNOLOGY 1-7 (January 2002).  |                |
|                        |              | #MUCHMORE et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human<br>Chorionic Gonadotropin is not Responsible, The Journal of Immunology, March 1997, pp. 881-86, Vol. 118, No. 3.  |                |
|                        |              | #MUCHMORE et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human<br>Pregnancy Urine, Journal of Experimental Medicine, December 1984, pp. 1672-85, Volume 160.  |                |
|                        |              | #PATIL, A., et al., "The Study of the Effect of Human Chorionic Gonadotrophic (HCG) Hormone on the Survival of Adrenal<br>Medulla Transplant in Brain. Preliminary Study," 87 ACTA NEUROCHIR (WIEN) 76-78 (1987).   |                |
|                        |              | #SLATER, Lewis M., et al., "Decreased Mortality of Murine Graft-Versus-Host Disease by Human Chorionic gonadotropin,<br>"23(1) TRANSPLANTATION 103-104 (January 1977).  |                |
|                        |              | #WULCZYN, F. Gregory, et al., "The NF-kB/Rel and I $\kappa$ B gene families: mediators of immune response and inflammation,"<br>74(12) J. MOL. MED. 749-769 (1996).   |                |
|                        |              | #YAMAMOTO, Y., et al., "Role of the NF-kB Pathway in the Pathogenesis of Human Disease States," 1(3) CURRENT<br>MOLECULAR MEDICINE 287-296 (July 2001).   |                |

Examiner  
SignatureDate  
ConsideredPursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the  
Office in the following prior application:

Serial No.: 09/821,380

Filed: March 29, 2001

For: IMMUNOREGULATOR, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

† EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not  
considered. Include copy of this form with next communication to applicant.<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the  
amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO  
NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





